Limits...
A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool.

Wang P, Guo YM, Liu M, Qiang YQ, Guo XJ, Zhang YL, Duan XY, Zhang QJ, Liang W - Korean J Radiol (2008 Sep-Oct)

Bottom Line: Using the homogeneity test, a statistical effect model was chosen to calculate different pooled weighted values of sensitivity, specificity, and the corresponding 95% confidence intervals (95% CI).The summary receiver operating characteristic (SROC) curves method was used to assess the results.In the second criterion, the pooled weighted sensitivity, specificity, and corresponding 95% CI were 0.64 (0.55, 0.72), 0.86 (0.79, 0.91) and 82.7% (68.73, 96.68).

View Article: PubMed Central - PubMed

Affiliation: The 2nd Affiliated Hospital of Medical School, Xioan Jiao Tong University, Imaging Center, Xi'an, Shannxi Province, China. yt.wangpeng813@163.com

ABSTRACT

Objective: We aimed to do a meta-analysis of the existing literature to assess the accuracy of prostate cancer studies which use magnetic resonance spectroscopy (MRS) as a diagnostic tool.

Materials and methods: Prospectively, independent, blind studies were selected from the Cochrane library, Pubmed, and other network databases. The criteria for inclusion and exclusion in this study referenced the criteria of diagnostic research published by the Cochrane center. The statistical analysis was adopted by using Meta-Test version 6.0. Using the homogeneity test, a statistical effect model was chosen to calculate different pooled weighted values of sensitivity, specificity, and the corresponding 95% confidence intervals (95% CI). The summary receiver operating characteristic (SROC) curves method was used to assess the results.

Results: We chose two cut-off values (0.75 and 0.86) as the diagnostic criteria for discriminating between benign and malignant. In the first diagnostic criterion, the pooled weighted sensitivity, specificity, and corresponding 95% CI (expressed as area under curve [AUC]) were 0.82 (0.73, 0.89), 0.68 (0.58, 0.76), and 83.4% (74.97, 91.83). In the second criterion, the pooled weighted sensitivity, specificity, and corresponding 95% CI were 0.64 (0.55, 0.72), 0.86 (0.79, 0.91) and 82.7% (68.73, 96.68).

Conclusion: As a new method in the diagnostic of prostate cancer, MRS has a better applied value compared to other common modalities. Ultimately, large scale RCT (randomized controlled trial) randomized controlled trial studies are necessary to assess its clinical value.

Show MeSH

Related in: MedlinePlus

Summary receiver operating characteristic curve of first diagnostic criterion - 0.75. Area under curve represents accuracy of diagnosis. Larger area, greater level of accuracy. Area under curve is 83.4% (74.97, 91.83).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2627206&req=5

Figure 2: Summary receiver operating characteristic curve of first diagnostic criterion - 0.75. Area under curve represents accuracy of diagnosis. Larger area, greater level of accuracy. Area under curve is 83.4% (74.97, 91.83).

Mentions: Because SROC can inflect a non-linear relationship between the sensitivity and specificity simultaneously, it was better used (18) to assess the accuracy of the diagnostic tests. Here we drew and analyzed SROC and calculated AUC for these two groups (Figs. 2, 3).


A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool.

Wang P, Guo YM, Liu M, Qiang YQ, Guo XJ, Zhang YL, Duan XY, Zhang QJ, Liang W - Korean J Radiol (2008 Sep-Oct)

Summary receiver operating characteristic curve of first diagnostic criterion - 0.75. Area under curve represents accuracy of diagnosis. Larger area, greater level of accuracy. Area under curve is 83.4% (74.97, 91.83).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2627206&req=5

Figure 2: Summary receiver operating characteristic curve of first diagnostic criterion - 0.75. Area under curve represents accuracy of diagnosis. Larger area, greater level of accuracy. Area under curve is 83.4% (74.97, 91.83).
Mentions: Because SROC can inflect a non-linear relationship between the sensitivity and specificity simultaneously, it was better used (18) to assess the accuracy of the diagnostic tests. Here we drew and analyzed SROC and calculated AUC for these two groups (Figs. 2, 3).

Bottom Line: Using the homogeneity test, a statistical effect model was chosen to calculate different pooled weighted values of sensitivity, specificity, and the corresponding 95% confidence intervals (95% CI).The summary receiver operating characteristic (SROC) curves method was used to assess the results.In the second criterion, the pooled weighted sensitivity, specificity, and corresponding 95% CI were 0.64 (0.55, 0.72), 0.86 (0.79, 0.91) and 82.7% (68.73, 96.68).

View Article: PubMed Central - PubMed

Affiliation: The 2nd Affiliated Hospital of Medical School, Xioan Jiao Tong University, Imaging Center, Xi'an, Shannxi Province, China. yt.wangpeng813@163.com

ABSTRACT

Objective: We aimed to do a meta-analysis of the existing literature to assess the accuracy of prostate cancer studies which use magnetic resonance spectroscopy (MRS) as a diagnostic tool.

Materials and methods: Prospectively, independent, blind studies were selected from the Cochrane library, Pubmed, and other network databases. The criteria for inclusion and exclusion in this study referenced the criteria of diagnostic research published by the Cochrane center. The statistical analysis was adopted by using Meta-Test version 6.0. Using the homogeneity test, a statistical effect model was chosen to calculate different pooled weighted values of sensitivity, specificity, and the corresponding 95% confidence intervals (95% CI). The summary receiver operating characteristic (SROC) curves method was used to assess the results.

Results: We chose two cut-off values (0.75 and 0.86) as the diagnostic criteria for discriminating between benign and malignant. In the first diagnostic criterion, the pooled weighted sensitivity, specificity, and corresponding 95% CI (expressed as area under curve [AUC]) were 0.82 (0.73, 0.89), 0.68 (0.58, 0.76), and 83.4% (74.97, 91.83). In the second criterion, the pooled weighted sensitivity, specificity, and corresponding 95% CI were 0.64 (0.55, 0.72), 0.86 (0.79, 0.91) and 82.7% (68.73, 96.68).

Conclusion: As a new method in the diagnostic of prostate cancer, MRS has a better applied value compared to other common modalities. Ultimately, large scale RCT (randomized controlled trial) randomized controlled trial studies are necessary to assess its clinical value.

Show MeSH
Related in: MedlinePlus